Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company's lead product candidate is ARIKAYCE or liposomal amikacin for inhalation, a formulation of amikacin that is in late-stage clinical development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by Mycobacterium avium complex. It is also developing INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1, which has completed a Phase I clinical study for activating neutrophil serine proteases that are implicated in the pathology of chronic inflammatory lung diseases, such as non-cystic fibrosis bronchiectasis; and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug, which has completed a Phase I clinical study for treating rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1999 and is headquartered in Bridgewater, New Jersey.
http://www.priceseries.com/trade/INSM-Insmed-Inc-stock-gains-25-percent-a-Trade-Record-by-priceSeries-2020041720200529.html
Related Posts :
- KOS Kosmos Energy Ltd. gains 15% Jan 19, 2022http://www.priceseries.com/trade/KOS-Kosmos-Energy-Ltd-stock-gains-15-percent-a-Trade-Rec…
- PFBC Preferred Bank gains 15% Jan 19, 2022Preferred Bank provides various commercial banking products and services to small and mid…
- ICD Independence Contract Drilling, Inc. gains 34% Jan 19, 2022Independence Contract Drilling, Inc. provides land-based contract drilling services for o…
- SAN Banco Santander, S.A. gains 15% Jan 19, 2022http://www.priceseries.com/trade/SAN-Banco-Santander-SA-stock-gains-15-percent-a-Trade-Re…
- PBCT Peoples United Financial, Inc. gains 17% Jan 19, 2022People's United Financial, Inc. operates as the bank holding company for People's United …
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments